Myths vs facts: CYP2C19 and Allergie

Myth: CYP2C19 gene variants determine your allergy risk. Fact: CYP2C19 is primarily a drug-metabolizing enzyme (e.g., for clopidogrel, proton pump inhibitors). There is no strong evidence linking CYP2C19 polymorphisms directly to allergy development or severity. Some direct-to-consumer tests may claim such links, but the supporting data are weak or inconsistent. Evidence level: unclear/marketing. Caveat: Do not base allergy management on this gene alone. Consult a physician for proper allergy diagnosis and treatment.